Bladder Cancer
Kidney Cancer
EAU Edu Platform on Prostate Cancer
Home
Articles
Article of the Month
Editorial
Videos
Webcasts
Education
Curriculum: mPCa patients treatment
Curriculum: CVD risk in PCa patients
E-courses
ESOU Online
Webinars
Guidelines
Events
Home
Articles
Terug
Article of the Month
Editorial
Videos
Webcasts
Education
Terug
Curriculum: mPCa patients treatment
Curriculum: CVD risk in PCa patients
E-courses
ESOU Online
Webinars
Guidelines
Events
Upcoming event
ESU-Weill Cornell Masterclass on General urology
Home
/
ASCO26
Back
Tag:
ASCO26
Cognitive effects of darolutamide vs enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology
View
TALAPRO-3: Talazoparib (TALA) + enzalutamide (ENZA) compared with placebo (PBO) + ENZA for the treatment of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations
View
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
I agree
Read More